首页> 美国卫生研究院文献>other >Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles
【2h】

Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles

机译:通过FVIII-壳聚糖纳米颗粒的口服传递基因转移至A型血友病小鼠

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Effective oral delivery of a non-viral gene carrier would represent a novel and attractive strategy for therapeutic gene transfer. To evaluate the potential of this approach, we studied the oral gene delivery efficacy of DNA polyplexes composed of chitosan and Factor VIII DNA. Transgene DNA was detected in both local and systemic tissues following oral administration of the chitosan nanoparticles to hemophilia A mice. Functional factor VIII protein was detected in plasma by chromogenic and thrombin generation assays, reaching a peak level of 2–4% FVIII at day 22 after delivery. In addition, a bleeding challenge one month after DNA administration resulted in phenotypic correction in 13/20 mice given 250–600 μg of FVIII DNA in chitosan nanoparticles, compared to 1/13 mice given naked FVIII DNA and 0/6 untreated mice. While further optimization would be required to render this type of delivery system practical for hemophilia A gene therapy, the findings suggest the feasibility of oral, non-viral delivery for gene medicine applications.
机译:有效地口服递送非病毒基因载体将代表治疗性基因转移的新颖且有吸引力的策略。为了评估这种方法的潜力,我们研究了由壳聚糖和凝血因子VIII DNA组成的DNA多链体的口服基因递送功效。在将甲壳素纳米颗粒口服给予血友病A小鼠后,在局部和全身组织中均检测到转基因DNA。通过发色和凝血酶生成分析在血浆中检测到功能性VIII蛋白质,在分娩后第22天达到FVIII的2-4%峰值水平。此外,与给予裸露的FVIII DNA的1/13小鼠和未经处理的0/6小鼠相比,DNA给药后一个月的出血激发导致13/20小鼠在250-600μg壳聚糖纳米颗粒中给予FVIII DNA的表型校正。尽管需要进一步优化以使这种类型的递送系统可用于A型血友病基因治疗,但研究结果表明,在基因药物应用中口服,非病毒递送的可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号